🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

🧪

Trial Match

Clinical trials test new treatments — sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

🎯 Match trials to me

30 recruiting trials

for EGFR

Bolstering Outcomes After Induction With Osimertinib Plus Chemotherapy Through Optimized Site-Directed Primary Tumor Therapy (BOOST Trial) NCT07073365Phase 21 site📍 Busan Pusan National University Hospital · Tests: Local Therapy (Surgery or Radiotherapy) A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment. NCT07062965Phase 3433 sites📍 Anchorage📍 Chandler📍 Gilbert Pfizer · Tests: PF-07248144, Fulvestrant, Everolimus, Exemestane Basal-like PDAC Treated With Gemcitabine, Erlotinib, and Nab-paclitaxel NCT06483555Phase 1, Phase 21 site📍 Chapel Hill UNC Lineberger Comprehensive Cancer Center · Tests: Gemcitabine, Nab paclitaxel, Erlotinib, NALIRIFOX, Folfirinox A Clinical Trial Evaluating TQB2102 for Injection in Combination With Behmosubaisumab/Payamprolizumab With or Without Chemotherapy in Unresectable Locally Advanced, Recurrent, or Metastatic Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastroesophageal Adenocarcinoma NCT06767800Phase 239 sites📍 Fuyang📍 Lu'an📍 Maanshan Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Phar… · Tests: TQB2102 for injection (7.5 mg) +Benmelstobart+Chemotherapy, TQB2102 for injection (6 mg/7.5 mg) +Benmelstobart+Chemothe… Telisotuzumab Vedotin and Osimertinib for the Treatment of Progressive, Incurable, Non Small Cell Lung Cancer NCT07323641Phase 21 site📍 Los Angeles Jonsson Comprehensive Cancer Center · Tests: Biopsy Procedure, Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging, Osimertinib FIH Study of RGT-419B Alone and With Endocrine Therapy in HR-Positive, HER2-Negative Advanced/Metastatic Breast Cancer NCT05304962Phase 18 sites📍 La Jolla📍 Los Angeles📍 Port Saint Lucie Regor Pharmaceuticals Inc. · Tests: RGT-419B, RGT-419B in combination with hormonal therapy Biologic Association Between Metabolic Magnetic Resonance-positron Emission Tomograph (MR-PET) and Tissue Measures of Glycolysis in Brain Tumors of Infiltrating Glioblastoma Cells NCT06059690Phase 1, Phase 21 site📍 Los Angeles Jonsson Comprehensive Cancer Center · Tests: pH Measurement of in vivo tissue A Study of Neoadjuvant Amivantamab With Either Lazertinib or Chemotherapy in Participants With Resectable EGFR-Mutated NSCLC NCT07586202Phase 223 sites📍 Duarte📍 Irvine📍 Portland Janssen Research & Development, LLC · Tests: Amivantamab, Lazertinib, Carboplatin, Pemetrexed Osimertinib for Advanced EGFR-positive NSCLC Patients NCT05037331n/a1 site📍 Singapore National University Hospital, Singapore A Study to Observe the Safety of VYLOY (Zolbetuximab) in People in South Korea With Gastric or Gastroesophageal Junction Cancer. NCT06902545n/a15 sites📍 Goyang-si📍 Suwon📍 Suwon Astellas Pharma Korea, Inc. · Tests: zolbetuximab EGFR Antibody Combined With PD-1 Inhibitor and Chemotherapy in R/M Nasopharyngeal Carcinoma NCT06802835Phase 1, Phase 21 site📍 Guangzhou Sun Yat-sen University · Tests: EGFR Antibody, PD-1 antibody, Gemcitabine, Cisplatin, IMRT Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer NCT06982521Phase 3243 sites📍 Gilbert📍 Beverly Hills📍 Duarte Relay Therapeutics, Inc. · Tests: Zovegalisib, Capivasertib, Fulvestrant TAR-0520 Gel in EGFR Inhibitor-induced Folliculitis NCT06818058Phase 23 sites📍 Lyon📍 Marseille📍 Nice Tarian Pharma · Tests: Brimonidine tartrate Gel, Placebo gel (no Brimonidine tartrate) Osimertinib to Suppress the Progression of Remaining GGN for EGFR Mutation-positive Stage IB-IIIA Lung Adenocarcinoma NCT05528458Phase 21 site📍 Seoul Samsung Medical Center · Tests: Osimertinib 80Mg Tab TY-9591 in the Patients With EGFR Mutations in Advanced NSCLC With Brain Metastases NCT05948813Phase 21 site📍 Beijing TYK Medicines, Inc · Tests: TY-9591, Osimertinib Metformin Plus Tyrosine Kinase Inhibitors for Treatment of Patients With Non-small Cell Lung Cancer With EGFR Mutations NCT05445791Phase 31 site📍 Mexico City Instituto Nacional de Cancerologia de Mexico · Tests: Metformin Hydrochloride, Placebo Evaluation of IRDye800CW-nimotuzumab in Lung Cancer Surgery NCT04459065Phase 1, Phase 21 site📍 Saskatoon University of Saskatchewan · Tests: IRDye800CW-nimotuzumab A Clinical Study of the Combination of Anlotinib and Aumolertinib in the First-line Treatment of Advanced NSCLC With EGFR 21L858R Mutation NCT06102928NA1 site📍 Kunming Kunming Medical University · Tests: Combined therapy of anlotinib and aumolertinib Safety and Preliminary Efficacy of VIR-5525 and VIR-5525 + Pembrolizumab in Participants With Locally Advanced or Metastatic Solid Tumors NCT06960395Phase 14 sites📍 Scottsdale📍 Houston📍 Wollongong Vir Biotechnology, Inc. · Tests: VIR-5525, Pembrolizumab A Study to Evaluate the Benefits and Risks of Conversion of Existing Adolescent Kidney Transplant Recipients Aged 12 to <18 Years to a Belatacept-based Immunosuppressive Regimen as Compared to Continuation of a Calcineurin Inhibitor-based Regimen, and Their Adherence to Immunosuppressive Medications NCT04877288Phase 338 sites📍 Birmingham📍 Los Angeles📍 Washington D.C. Bristol-Myers Squibb · Tests: Belatacept, Tacrolimus, Cyclosporine A, Mycophenolate Mofetil, Enteric Coated Mycophenolate Sodium Phase 1 Trial of D2C7-IT in Combination With 2141-V11 for Recurrent Malignant Glioma NCT04547777Phase 11 site📍 Durham Darell Bigner · Tests: D2C7-IT, 2141-V11 IN10018 Combination Therapy in Advanced EGFR Mutation-positive NSCLC NCT05994131Phase 1, Phase 21 site📍 Shanghai InxMed (Shanghai) Co., Ltd. · Tests: IN10018, Furmonertinib Study of Efficacy and Safety of Iptacopan in Participants With IC-MPGN NCT05755386Phase 3131 sites📍 Los Angeles📍 Orange📍 San Francisco Novartis Pharmaceuticals · Tests: Placebo, iptacopan EGFR-ADC (Becotatug Vedotin) Combined With PD-1 Inhibitor (Pucotenlimab) in Neoadjuvant Treatment of Advanced Penile Cancer NCT07518979Phase 21 site📍 Chengdu Jiyan Liu · Tests: Becotatug Vedotin, Pucotenlimab Neo-Bio-ADAURA: a Phase II Study to Evaluate Mechanisms of Resistance to Neoadjuvant Osimertinib NCT06206850Phase 22 sites📍 Ramat Gan📍 Ramat Gan Jair Bar, M.D., Ph.D. · Tests: Osimertinib Temozolomide, With or Without WSD0922-FU, for the Treatment of EGFR-Mutant, IDH-Wildtype Glioblastoma NCT07708961Phase 23 sites📍 Scottsdale📍 Jacksonville📍 Rochester Mayo Clinic · Tests: Archive Sample Retrieval, Biospecimen Collection, Chest Radiography, Echocardiography Test, EGFR/EGFRvIII Inhibitor WSD… A Rollover Extension Program (REP) to Evaluate the Long-term Safety and Tolerability of Open Label Iptacopan/LNP023 in Participants With Primary IgA Nephropathy NCT04557462Phase 3161 sites📍 Glendale📍 San Diego📍 San Dimas Novartis Pharmaceuticals · Tests: LNP023 Vebreltinib Plus PLB1004 in EGFR-mutated, Advanced NSCLC With MET Amplification or MET Overexpression Following EGFR-TKI NCT06343064Phase 1, Phase 21 site📍 Shanghai Avistone Biotechnology Co., Ltd. · Tests: Vebreltinib, PLB1004 A Global Phase III Study of Rilvegostomig or Pembrolizumab Monotherapy for First-Line Treatment of PD-L1-high Metastatic Non-small Cell Lung Cancer NCT06868277Phase 3304 sites📍 La Mesa📍 Los Alamitos📍 Newark AstraZeneca · Tests: Rilvegostomig, Pembrolizumab A ctDNA-guided Phase II Trial of Osimertinib in Combination With Sacituzumab Tirumotecan in EGFR-mutated Advanced NSCLC Patients With Positive ctDNA After lead-in Osimertinib Monotherapy NCT07375316Phase 24 sites📍 Guangzhou📍 Meizhou📍 Shantou Guangdong Association of Clinical Trials · Tests: Osimertinib + Sacituzumab Tirumotecan, Osimertinib
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy